Disease relevance of Irloxacin

• As a summary, the results have shown that irloxacin has a low acute toxicity in both mice and rats [1].
• The synthesis and antimicrobial activities against Gram-positive and Gram-negative bacteria of some 1-substituted quinolones related to pirfloxacin are reported [2].

High impact information on Irloxacin

• In vitro activities of irloxacin and E-3846, two new quinolones [3].
• Developmental toxicity studies of the quinolone antibacterial agent irloxacin in rats and rabbits [4].
• Oral administration of irloxacin during the fetal period of organogenesis to pregnant rats and rabbits at dose levels of up to 1000 and 350 mg/kg/d, respectively, elicited no evidence of teratogenicity [4].
• The results obtained showed that irloxacin was well tolerated after single administration in mice and rats, with LD50 values above 2000 and 5000 mg/kg for intraperitoneal and oral administration, respectively [1].
• Irloxacin (6-fluorine-7-(pyrrol-1-yl)-1-ethyl-1, 4-dihydro-4-oxo-quinolone-3-carboxylic acid, CAS 91524-15-1), a new quinolone antibacterial agent, was administered as a single dose to rats and mice both by oral and intraperitoneal route in oder to study its acute toxicity [1].

References